Have any questions? +91-891- 2878787, +91-891- 2551811, info@mgcancerhospital.com

Selected Ongoing Studies

Clinical Study Principal Investigator
Mylan – Cliantha  MYL-1402O-3001 : Multicentre, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First -line  treatment of Patient with Stage IV Non-Squamous Non-Small Cell Lung Cancer.(Recruitment ongoing) Dr. Karthik Chandra Vallam
TevaPharma -Lotus  –Study Title: An Open-Label, Multicentric, Randomized, Two Treatment, Three Period, Three Sequence, Semi-Replicate, Cross-over, Comparative Bioavailability Study of Doxorubicin Hydrochloride Liposomal Injection 20 mg/10mL (2mg/ml), concentrate for solution for infusion manufactured by Teva Pharmachemie, Netherlands with Caelyx 20 mg/10ml (2mg/ml) [Doxorubicin Hydrochloride Liposomal Injection], concentrate for solution for infusion of Janssen-CilagInternational NV, Belgium in advanced ovarian cancer and/or metastatic breast cancer patients under fasting condition. CT/DOX/1602. (Recruitment ongoing) Dr. Murali Krishna Voonna
Dr. Reddy’s -SMO India -17-VIN-0028-An open label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, multi center, multiple dose steady state bioequivalence study of Everolimus tablets 10 mg of Dr. Reddy’s Laboratories Limited, India comparing with that of AFINITOR® (everolimus) tablets 10 mg, Manufactured by Novartis Pharma Stein AG Stein, Switzerland in adult subjects of advanced renal cell carcinoma (RCC) who are already receiving everolimus at a stable dose of 10 mg once a day as their individual therapy. (Recruitment ongoing) Dr. Murali Krishna Voonna
Dr. Reddy’s – Lambda Study No.0076-17  –A multicenter, open label, randomized, two-treatment, two-period, two-sequence, single dose, cross-over bioequivalence study of Doxorubicin Hydrochloride (Pegylated liposomal) concentrate for solution for infusion 20 mg/10mL (2 mg/mL) of Dr. Reddy’s Laboratories Ltd, India, with that of Caelyx® 2mg/mL [Doxorubicin Hydrochloride (Pegylated Liposomal) concentrate for solution for infusion (20 mg/10mL)] of Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium in advanced ovarian cancer and/or metastatic breast cancer patients under fed condition. (Recruitment ongoing) Dr. Rakesh Reddy Boya
Reference: Protocol no: CLR_16_13 – Sun Pharma Study Title: A randomized, open-label, two-period, single-dose, crossover, bioavailability study of paclitaxel injection concentrate for nano-dispersion (PICN) and Abraxane® in subjects with locally recurrent or metastatic breast cancer. (Recruitment ongoing) Dr. Rakesh Reddy Boya
Intas -Lambda Therapeutic Research Ltd Study No.471-13-A Prospective, Adaptive, Randomized, Open-Label, MulticenterClinical Trial to assess the Efficacy and Safety of Fixed DoseCombination of Capecitabine & Cyclophosphamide in Patients of Metastatic Breast Cancer with failure of Anthracyclineand/or Taxane Chemotherapy. (Recruitment ongoing) Dr. Rakesh Reddy Boya
A Randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies That Target HER2 Receptors In Combination With Weekly Paclitaxel Administered As First-Line Treatment In Patients With HER2-Positive Metastatic Breast (Recruitment ongoing) Dr. Murali Krishna Voonna
A randomized double-blind study in two parts

  • PartA – Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC)
  • PartB – Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced non-squamous non-small cell lung cancer(NSCLC)
    (Recruitment ongoing)
Dr. Karthik Chandra Vallam
A Phase 3 Randomized, Double-Blind Study Of Pf-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin For The First-Line Treatment Of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer(Follow-Up Phase, Recruitment Completed) Dr. Murali Krishna Voonna